OBJECTIVE - We aim to investigate the pharmacokinetics and distribution of the recently clinically introduced radioligand (68)Ga-PSMA-11 in men with recurrent prostate cancer (PC) by means of dynamic and whole-body PET/CT.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The correlation between PSA levels and (68)Ga-PSMA-11 PET parameters is also investigated.
METHODS - 31 patients with biochemical failure after primary PC treatment with curative intent (median age 71. 0 years) were enrolled in the analysis. The median PSA value was 2. 0 ng/mL (range = 0. 1 - 130. 0 ng/mL) and the median Gleason score was 7 (range = 5 - 9). 8/31 (25. 8 %) of the included patients had a PSA value < 0. 5 ng/ml. All patients underwent dynamic PET/CT (dPET/CT) scanning (60 min) of the pelvis and lower abdomen as well as whole-body PET/CT with (68)Ga-PSMA-11. dPET/CT assessment was based on qualitative evaluation, SUV calculation, and quantitative analysis based on a two-tissue compartment model and a non-compartmental approach leading to the extraction of fractal dimension (FD).
RESULTS - 22/31 patients (71. 0 %) were (68)Ga-PSMA-11-positive, while 9/31 (29. 0 %) patients were (68)Ga-PSMA-11-negative. The median PSA value in the (68)Ga-PSMA-11-positive group was significantly higher (median = 2. 35 ng/mL; range = 0. 19 - 130. 0 ng/mL) than in the (68)Ga-PSMA-11-negative group (median value: 0. 34 ng/mL; range = 0. 10 - 4. 20 ng/mL). A total of 76 lesions were semi-quantitatively evaluated. PC recurrence-associated lesions demonstrated a mean SUVaverage = 12. 4 (median = 9. 0; range = 2. 2 - 84. 5) and mean SUVmax = 18. 8 (median = 14. 1; range = 3. 1 - 120. 3). Dynamic PET/CT studies of the pelvis revealed the following mean values for the PC recurrence-suspicious lesions: K1 = 0. 26, k3 = 0. 30, influx = 0. 14 and FD = 1. 24. Time-activity curves derived from PC-recurrence indicative lesions revealed an increasing (68)Ga-PSMA-11 accumulation during dynamic PET acquisition. Correlation analysis revealed a moderate, but significant, correlation between PSA levels and the number of lesions detected on (68)Ga-PSMA-11 PET/CT (r = 0. 54) and between PSA levels and SUVaverage (r = 0. 48) or SUVmax (r = 0. 44).
CONCLUSIONS - Ga-PSMA-11 PET/CT demonstrated an overall detection rate of 71. 0 % 60 min p. i. of the radiotracer in a mixed patient population with respect to PSA levels and including patients with very low PSA values. Higher PSA values were associated with a higher detection rate. The tracer uptake in PC-recurrence-indicative lesions is increasing during the 60 minutes of dynamic PET acquisition.
European journal of nuclear medicine and molecular imaging. 2016 Jan 12 [Epub ahead of print]
C Sachpekidis, M Eder, K Kopka, W Mier, B A Hadaschik, U Haberkorn, A Dimitrakopoulou-Strauss
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany. , Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany. , Division of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany. , Department of Urology, University Hospital Heidelberg, Heidelberg, Germany. , Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. , Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.